Business UpdateJun 15, 2026, 07:11 AM
Lexeo Therapeutics Finalizes LX2006 Pivotal Trial Design for FA Cardiomyopathy
AI Summary
Lexeo Therapeutics announced significant regulatory updates for its gene therapy candidate LX2006, targeting Friedreich ataxia (FA) cardiomyopathy. The company has finalized the pivotal SUNRISE-FA 2 trial protocol and statistical analysis plan, designed to support a Biologics License Application (BLA) for accelerated approval, with a potential submission in the first half of 2028. The study is on track to initiate in Q2 2026, with topline data anticipated in the second half of 2027. Clinical drug product is ready for patient dosing.
Key Highlights
- Lexeo Therapeutics finalized the SUNRISE-FA 2 pivotal trial protocol and SAP for LX2006 gene therapy in Friedreich ataxia (FA) cardiomyopathy.
- The pivotal study aims to support a Biologics License Application (BLA) under the accelerated approval pathway, with a potential submission in 1H 2028.
- Study initiation is on track for Q2 2026, with the first patient expected to be enrolled by the end of June 2026.
- Topline data readout is expected in the second half of 2027.
- The SUNRISE-FA 2 study is an open-label trial with 13 participants receiving LX2006 and 13 untreated controls.
- The primary endpoint is Left Ventricular Mass Index (LVMI) at 6 months post-treatment.
- The company also announced that clinical drug product has been manufactured at commercial scale and is available for patient dosing.
Price Impact
More from LXEO